Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-nishi, Ota-ku, Tokyo, 143-8540, Japan.
Department of Translational Research & Cellular Therapeutics, Faculty of Medicine, Toho University, 5-21-16 Omori-nishi, Ota-ku, Tokyo, 143-8540, Japan.
Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):581-589. doi: 10.1007/s00210-020-01997-w. Epub 2020 Oct 16.
Donepezil, an inhibitor for acetylcholinesterase used for patients with Alzheimer's disease, has been shown to inhibit I, occasionally inducing torsade de pointes. In order to analyze the causal relationship between donepezil treatment and onset of lethal arrhythmias, we initially assessed electropharmacological effects of donepezil hydrochloride of 0.01, 0.1, and 1 mg/kg, i.v. over 10 min using the halothane-anesthetized intact dogs (n = 4), possibly providing subtherapeutic to supratherapeutic plasma concentrations. Although the low or middle dose did not exert any effect, the high dose transiently increased the ventricular refractoriness along with modest prolongation of the late repolarization period, indicating potential I inhibitory action in vivo. Moreover, the high dose induced the positive chronotropic, inotropic, and dromotropic actions along with the pressor effect and prolongation of early repolarization period, suggesting sympathicotonic condition in the central nervous system. Next, we examined proarrhythmic effects of donepezil hydrochloride of 0.1 and 1 mg/kg, i.v. over 10 min using the conscious chronic atrioventricular block dogs (n = 4). Although the low dose hardly affected the cardiovascular variables, the high dose increased the atrial and ventricular rate without significantly altering the repolarization period, possibly reflecting sympathicotonic condition. Importantly, the high dose induced non-sustained ventricular tachycardia in half of the animals. Thus, donepezil by itself did not induce torsade de pointes in vivo, which suggests that donepezil-induced sympathicotonic condition may induce Ca overload, triggering the ventricular arrhythmias, but might indirectly attenuate its I inhibitory action, preventing excessive repolarization delay.
多奈哌齐是一种乙酰胆碱酯酶抑制剂,用于治疗阿尔茨海默病患者,已被证明可抑制 I 相,偶尔会引起尖端扭转型室性心动过速。为了分析多奈哌齐治疗与致死性心律失常发作之间的因果关系,我们最初评估了 0.01、0.1 和 1mg/kg 的多奈哌齐盐酸盐静脉注射 10 分钟对氟烷麻醉的完整犬(n=4)的电药理学效应,可能提供治疗范围下限至治疗范围上限的血浆浓度。虽然低剂量或中剂量没有产生任何作用,但高剂量会短暂增加心室不应期,同时适度延长晚期复极期,表明体内存在潜在的 I 抑制作用。此外,高剂量还会引起正性变时、变力和变传导作用,以及升压作用和早期复极期延长,提示中枢神经系统存在交感神经紧张。接下来,我们使用清醒慢性房室传导阻滞犬(n=4),静脉注射 0.1 和 1mg/kg 的多奈哌齐盐酸盐 10 分钟,检测其致心律失常作用。虽然低剂量几乎不会影响心血管变量,但高剂量会增加心房和心室率,而不会显著改变复极期,这可能反映了交感神经紧张。重要的是,高剂量会引起一半动物非持续的室性心动过速。因此,多奈哌齐本身不会在体内引起尖端扭转型室性心动过速,这表明多奈哌齐引起的交感神经紧张可能会导致 Ca 超载,引发室性心律失常,但可能会间接减弱其 I 抑制作用,防止过度复极延迟。